TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer Clinical Trial

Official title:
A Randomized, Open-label, Single-center, Phase III Trial Comparing Docetaxel Plus Carboplatin (TCb) Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel (EC-T) Regimen as Adjuvant Chemotherapy in Patients With LN≥4 Estrogen Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Breast Cancer

Status Recruiting

Clinical Trial Summary

This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Hormone Receptor Positive HER-2 Negative Breast Cancer

Clinical Trial Details

NCT number	NCT05901428
Study type	Interventional
Source	Fudan University
Contact
Status	Recruiting
Phase	Phase 3
Start date	June 1, 2023
Completion date	June 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02692755` - Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer	Phase 2/Phase 3
Not yet recruiting	`NCT06201234` - Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer	Phase 2
Recruiting	`NCT05573126` - Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT06257264` - A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors	Phase 1
Recruiting	`NCT05608252` - VS-6766+Abema+Fulv in Met HR+/HER- BC	Phase 1/Phase 2
Not yet recruiting	`NCT06369285` - A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer	Phase 2
Recruiting	`NCT06120283` - BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors	Phase 1
Recruiting	`NCT05878314` - Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer